Thursday 16 October, 2025
Background C-reactive protein (CRP), a marker of inflammation, positively correlates with disease aggressiveness and poor prognosis in advanced cancers including…
Read moreOral: Drug/Disease Modelling - Oncology
Modelling real-world tumor size dynamics based on electronic health records and image data in advanced melanoma patients receiving immunotherapy
Thursday 16 October, 2025
Objectives: Immune checkpoint inhibitors (ICIs) such as ipilimumab (CTLA4 inhibitor), nivolumab or pembrolizumab (PD1 inhibitors) have revolutionized cancer therapy with…
Read moreDevelopment and Application of a Minimal Physiology-based Pharmacokinetics Modelling Framework to Predict Tumor Penetration and Receptor Occupancy.
Thursday 16 October, 2025
Objectives: In oncology drug development, rapid dose optimization is pivotal to allow timely patient benefit. For this, the FDA’s Project…
Read moreA physiologically-based pharmacokinetic/pharmacodynamic framework to support clinical development of V937, a novel oncolytic virus
Thursday 16 October, 2025
Objectives: Immuno-oncology (IO), based on the activation of the endogenous anti-tumor immune response, is a growing strategy in cancer treatment….
Read moreModeling the dynamics of anti-drug antibodies in cancer patients treated with oncolytic virus in monotherapy or in combination with immune check- point inhibitors
Thursday 16 October, 2025
Introduction and Objectives: Immuno-oncology (IO) therapeutic strategies, such as oncolytic viruses (OVs), are based on the activation of the endogenous anti-tumor…
Read moreAN INCIDENCE-SEVERITY MODEL FOR CYTOKINE RELEASE SYNDROME FOLLOWING DOSE-PRIMING REGIMENS OF ELRANATAMAB
Thursday 16 October, 2025
Introduction: Cytokine Release Syndrome (CRS) is a common adverse event with bispecific antibody (BsAb) therapy. Dose-priming regimens are routinely devised…
Read moreOptimizing Sunitinib Dosing in mRCC: Addressing Confounding Bias and Immortal Time Bias in Exposure- and Toxicity-survival Analyses using a Multistate Survival Modeling Framework
Thursday 16 October, 2025
Objectives: Sunitinib was approved by the FDA in 2006 and remains the most cost-effective first-line treatment for metastatic renal cell…
Read moreDevelopment of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental design
Thursday 16 October, 2025
Introduction: Chimeric antigen receptor-T cell (CAR-T) therapy is a novel cellular immunotherapy and has achieved impressive treatment outcomes for many…
Read more